肿瘤研究与临床最新文献

{"title":"Value of tumor diameter to preoperative carcinoembryonic antigen ratio in evaluating prognosis of non-metastatic colorectal cancer patients","authors":"R. Xu, Tao Yang, T. Xue, Tong-xin Yang","doi":"10.3760/CMA.J.CN115355-20190613-00250","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190613-00250","url":null,"abstract":"Objective \u0000To explore the value of tumor diameter to preoperative carcinoembryonic antigen (CEA) ratio (TCR) in predicting prognosis of patients with non-metastatic colorectal cancer. \u0000 \u0000 \u0000Methods \u0000The clinical data of 144 patients with colorectal cancer in Hainan Hospital of PLA General Hospital between July 2012 and December 2017 were retrospectively analyzed. Patients were divided into the low TCR group and the high TCR group according to the optimal value of TCR in predicting the disease-free survival (DFS) determined by the receiver operating characteristic curve (ROC). The clinicopathological features of both groups were analyzed, and the influencing factors of DFS were also analyzed by using Cox proportional hazard model. \u0000 \u0000 \u0000Results \u0000ROC analysis showed that TCR had a certain value in predicting DFS, and area under the curve (AUC) was 0.614 (95% CI 0.507-0.722); when the value of TCR was set at 0.690, the sensitivity and specificity of predicting the 3-year DFS rate was 46.3% and 70.9%, respectively. According to 0.690 of TCR, there were 50 cases in the low TCR ( 0.05). Univariate analysis showed that TCR, preoperative CEA level and TNM stage played a role in predicting DFS of patients (all P < 0.05), while Cox multivariate analysis indicated that TCR < 0.690 (HR = 2.369, 95% CI 1.279-4.388, P = 0.006) and Ⅲ stage in TNM stage (HR = 2.214, 95% CI 1.346-3.640, P = 0.002) were the independent risk factors of influencing DFS (all P < 0.01). The 3-year DFS rate of patients in the low TCR group was lower than that of those in the high TCR group (62.0% vs. 83.0%, P = 0.007). \u0000 \u0000 \u0000Conclusion \u0000TCR could have a certain value in judging the prognosis of non-metastatic colorectal cancer patients, and low TCR patients have a poorer prognosis. \u0000 \u0000 \u0000Key words: \u0000Colorectal neoplasms; Tumor diameter; Carcinoembryonic antigen; Disease-free survival; Prognosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"149-153"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47865754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of the relationship between high mobility group protein A2 and tumors","authors":"Kai Li, Q. Fu","doi":"10.3760/CMA.J.CN115355-20190618-00256","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190618-00256","url":null,"abstract":"High mobility group protein A2 (HMGA2) is a non-histone protein that does not have transcriptional activity by itself, but it changes its structure by binding to chromatin, which in turn regulates the transcription of other genes, thereby promoting tumor invasion and metastasis. The related RNA gene can regulate the role of HMGA2 in tumors, and the invasiveness of tumors is closely related to epithelial-mesenchymal transition (EMT), which can treat the related tumors by targeting HMGA2 gene. This article reviews the progress of the relationship between HMGA2 and tumors. \u0000 \u0000 \u0000Key words: \u0000High mobility group proteins; Molecular targeted therapy; RNA; Epithelial-mesenchymal transition","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"202-205"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45217172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of molecular markers related to papillary thyroid carcinoma","authors":"Xiaopan Li, Xi'an Lu","doi":"10.3760/CMA.J.CN115355-20190814-00359","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190814-00359","url":null,"abstract":"Papillary thyroid carcinoma is the most common malignant tumor in the head and neck. The incidence of papillary thyroid carcinoma has been increasing in recent years. Although the prognosis of most papillary thyroid carcinoma is better, many patients have poor prognosis due to recurrence or metastasis. Molecular markers play an important role in the development, diagnosis, treatment and prognosis of papillary thyroid carcinoma. This paper reviews the progress of molecular markers related to papillary thyroid carcinoma. \u0000 \u0000 \u0000Key words: \u0000Thyroid neoplasms; Carcinoma, papillary; Molecular markers; Prognosis; Treatment","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"209-212"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43595627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy observation of apatinib combined with capecitabine in the treatment of advanced esophageal cancer","authors":"H. Ye, Xiao-xiang Yin, Ying Zhao, L. Gu","doi":"10.3760/CMA.J.CN115355-20190515-00202","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190515-00202","url":null,"abstract":"Objective \u0000To observe the efficacy of apatinib combined with capecitabine in the treatment of advanced esophageal cancer. \u0000 \u0000 \u0000Methods \u0000A total of 101 patients with advanced esophageal cancer in Taixing People's Hospital of Jiangsu Province from June 2017 to February 2018 were enrolled, and all the patients were divided into the control group (50 cases) and the observation group (51 cases) according to the random number table. The control group was treated with capecitabine combined with radiotherapy, and the observation group was treated with apatinib on the basis of the control group. The therapeutic effects, adverse reactions and progression-free survival (PFS) time of the two groups were compared. \u0000 \u0000 \u0000Results \u0000The overall response rate in the observation group was higher than that in the control group [90.2% (46/51) vs. 72.0% (36/50)], and the difference was statistically significant (χ2 = 5.473, P = 0.019). There were no significant differences in leukopenia, neutropenia, thrombocytopenia, anemia, proteinuria and hypertension between the two groups (all P > 0.05). The median PFS time in the observation group was 18.49 months (95% CI 15.35-25.03 months), and that in the control group was 13.33 months (95% CI 10.36-18.24 months), and the difference between the two groups was statistically significant (χ2 = 5.995, P < 0.01). \u0000 \u0000 \u0000Conclusions \u0000The therapeutic effect of apatinib combined with capecitabine in the treatment of advanced esophageal cancer is accurate. No obvious adverse reaction occurs, and the PFS time is prolonged. \u0000 \u0000 \u0000Key words: \u0000Esophageal neoplasms; Drug therapy, combination; Apatinib; Capecitabine","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"170-173"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48194141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of serum thyroid hormone level with recurrence in patients with breast cancer after radical mastectomy","authors":"Hai-bin Lu, Xiaozhong Ji","doi":"10.3760/CMA.J.CN115355-20190909-00408","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190909-00408","url":null,"abstract":"目的 \u0000探讨乳腺癌根治术后患者血清甲状腺激素（TH）水平变化及其与术后复发的相关性。 \u0000 \u0000 \u0000方法 \u0000选取2017年1月至2019年1月于江苏省海安市人民医院行乳腺癌根治术的患者112例为乳腺癌组，选取同期健康体检者60名为对照组，采用化学发光免疫法测定两组血清促甲状腺激素（TSH）、游离三碘甲状腺原氨酸（FT3）、游离四碘甲状腺原氨酸（FT4）、总四碘甲状腺原氨酸（T4）、总三碘甲状腺原氨酸（T3）水平。根据术后复发情况分为复发组和未复发组，比较两组血清TH水平。 \u0000 \u0000 \u0000结果 \u0000乳腺癌组术前血清T3、FT3及FT4水平[（1.58±0.27）nmol/L、（4.42±0.49）pmol/L、（9.68±1.26）pmol/L]均低于对照组[（2.05±0.33）nmol/L、（4.94±0.58）pmol/L、（11.17±1.65）pmol/L]（均P<0.05），术后血清T3、FT3及FT4水平[（1.96±0.30）nmol/L、（4.75±0.51）pmol/L、（10.52±1.37）pmol/L]均高于术前（均P<0.05）。TNM分期Ⅰ期患者血清T3、FT3及FT4水平高于Ⅱ、Ⅲ期患者（均P<0.05），Ⅱ期患者血清T3、FT3及FT4水平高于Ⅲ期患者（均P<0.05）。乳腺癌患者未复发组术前血清T3、FT3及FT4水平均高于复发组（均P<0.05）。 \u0000 \u0000 \u0000结论 \u0000T3、FT3及FT4水平随疾病进展进行性降低，乳腺癌根治术后由于病灶组织的清除引起神经递质的改变，从而导致血清T3、FT3及FT4水平的增加，复发患者T3、FT3及FT4水平低于未复发患者，考虑乳腺癌复发与甲状腺功能异常有关。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"192-195"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44278345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of neutrophil-to-lymphocyte ratio in the diagnosis and prognosis evaluation of primary hepatocellular carcinoma","authors":"Yingwei Pan, XiangFei Meng, Lingyue Zhou, Zhiqiang Wang, Hangyu Zhang, Shi-xin Lu","doi":"10.3760/CMA.J.CN115355-20190906-00400","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190906-00400","url":null,"abstract":"Objective \u0000To investigate the value of neutrophil-to-lymphocyte ratio (NLR) in the diagnosis and prognosis evaluation of primary hepatocellular carcinoma. \u0000 \u0000 \u0000Methods \u0000The clinical data of 100 patients pathologically diagnosed as primary liver cancer who were admitted to the First Medical Center of Chinese PLA General Hospital from January 2013 to December 2015 were retrospectively analyzed. Serum alpha fetoprotein (AFP), a conventional marker for hepatocellular carcinoma diagnosis was used as the control. The fourfold table diagnostic test was applied to analyze the sensitivity and specificity of serum NLR in the diagnosis of hepatocellular carcinoma, and the correlation with the degree of tumor differentiation was also analyzed. \u0000 \u0000 \u0000Results \u0000The proportion of patients with high NLR (≥1.70) [56% (56/100)] was higher than the proportion of patients with positive AFP [44% (44/100)] in all 100 hepatocellular carcinoma patients, but the difference was not statistically significant (χ2 = 2.88, P = 0.08). Among AFP-positive patients, the median survival time of patients with low and high NLR was 59 and 48 months, respectively, and the difference was statistically significant (χ2 = 3.91, P = 0.048), and high NLR was an independent risk factor affecting the prognosis of hepatocellular carcinoma patients (HR = 1.232, 95% CI 1.055-1.438, P = 0.008). \u0000 \u0000 \u0000Conclusions \u0000The detection of NLR combined with AFP can improve the diagnostic rate of hepatocellular carcinoma before surgery. High NLR is an independent risk factor affecting the prognosis of patients with primary hepatocellular carcinoma. \u0000 \u0000 \u0000Key words: \u0000Liver neoplasms; Neutrophil-to-lymphocyte ratio; Diagnosis; Prognosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"157-160"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44358476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of the relationship between breast cancer and thyroid diseases","authors":"Weigang Wang, Bao-guo Tian, Yan Wang","doi":"10.3760/CMA.J.CN115355-20190227-00056","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190227-00056","url":null,"abstract":"Breast cancer and thyroid diseases mostly occur in women, and both have seriously affected women's physical and mental health. Breast cancer patients have a higher risk of thyroid diseases before and after the onset of the disease compared with other malignant tumors. There are some common risk factors between them, and breast and thyroid are hormone-responsive organs, so they can also influence each other in some regulatory pathways. Iodine, thyroid hormone receptor and estrogen receptor are considered to be the possible pathogenesis of breast cancer. This paper explores the relationship between breast cancer and thyroid diseases with the help of researches in breast cancer, thyroid benign diseases, thyroid cancer, thyroid hormones and antibodies in recent years, so as to provide a basis for disease prevention and treatment. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Thyroid diseases; Thyroid hormone receptor; Estrogen receptor","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"206-209"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42904112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of cancer incidence and mortality in registration areas of Shanxi Province in 2014","authors":"Zhao-hui Ma, Q. Gao, Ling Cao, Xinzheng Wang, Xue-rong Guo, Xinchen Wang, Fang Su, N. Qiao, Yuan Wang, Ruifeng Zhang, Yong-zhen Zhang","doi":"10.3760/CMA.J.CN115355-20191030-00492","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20191030-00492","url":null,"abstract":"Objective \u0000To explore the cancer incidence and mortality in registration areas of Shanxi Province in 2014. \u0000 \u0000 \u0000Methods \u0000The data of 12 cancer registration areas of Shanxi Province in 2014 were taken to analyze the characteristics of cancer incidence and mortality for patients with different age and gender in different areas. And then the results were compared with the malignant cancer incidence and mortality in the nationwide. \u0000 \u0000 \u0000Results \u0000There were 11 703 new cases, including 6 559 males and 5 144 females in registration areas of Shanxi Province in 2014, and the incidence rate was 221.21/105, while the age-standardized incidence rate of Chinese population and world population was 163.91/105 and 163.25/105, respectively. The cancer incidence rate in urban areas was 247.02/105 and the age-standardized incidence rate of Chinese population was 171.35/105. In rural areas, the cancer incidence rate was 205.98/105 and the age-standardized incidence rate of Chinese population was 159.03/105. The common cancer sites were stomach, lung, esophagus, liver and colorectum for males. And breast, cervix, lung, esophagus, stomach were the common cancer sites for females. There were 7 283 malignant death cases, including 4 548 males and 2 735 females. The crude cancer mortality rate was 137.66/105, and the age-standardized mortality rate of Chinese population was 99.67/105 and world population was 100.11/105. The crude cancer mortality rate in urban areas was 141.03/105 and the age-standardized incidence rate of Chinese population was 92.84/105. In rural areas, the crude cancer mortality rate was 135.68/105 and the age-standardized mortality rate of Chinese population was 103.69/105. Male common malignant tumor deaths included lung cancer, gastric cancer, liver cancer, esophageal cancer and colorectal cancer, while lung, stomach, liver, esophagus and cervix were the common cancer death sites for females. \u0000 \u0000 \u0000Conclusions \u0000The incidence and mortality of malignant tumors in registration areas in Shanxi Province are mainly lung cancer, upper gastrointestinal cancer and cervix uteri cancer. The incidence rates of stomach cancer and cervical cancer are high. \u0000 \u0000 \u0000Key words: \u0000Malignant neoplasms; Incidence analysis; Mortality analysis; Cancer registry","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"186-191"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42992343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of microsatellite instability for the prognosis and efficacy prediction in gastric cancer","authors":"Linghua Meng, Hai-Zhi Wu, T. Liang","doi":"10.3760/CMA.J.CN115355-20190623-00265","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190623-00265","url":null,"abstract":"Microsatellite instability (MSI) is caused by the deficiency of DNA mismatch repair (MMR) protein, which is closely related to the occurrence, development, prognosis and efficacy prediction of various tumors. MSI-high (MSI-H) and mismatch repair protein deficiency (dMMR) might be a predictor factor for the good prognosis of patients with gastric cancer, and a negative predictor factor for the chemotherapy efficacy of resectable gastric cancer. MSI-H/dMMR can be used as a marker for predicting the effective treatment outcome of immune checkpoint inhibitors in advanced gastric cancer, however, the predictive role in palliative chemotherapy of advanced gastric cancer is still unclear. This paper reviews the progress of the association of MSI/MMR with prognosis and efficacy prediction in gastric cancer. \u0000 \u0000 \u0000Key words: \u0000Stomach neoplasms; Microsatellite instability; Mismatch repair protein; Prognosis; Efficacy prediction","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"213-216"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44475614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in neoadjuvant therapy for rectal cancer","authors":"Lili Liu, B. Chang, Haiyi Liu, Yixun Zhang, Maoxin Liu, Li-chun Wang, Haibo Wang","doi":"10.3760/CMA.J.CN115355-20190509-00191","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190509-00191","url":null,"abstract":"Objective \u0000To investigate the significance of changes of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in neoadjuvant therapy for rectal cancer. \u0000 \u0000 \u0000Methods \u0000The data of 86 patients with rectal cancer who received neoadjuvant therapy from November 2013 to January 2015 in Shanxi Provincial Cancer Hospital were retrospectively analyzed, and the correlations of NLR and PLR changes with the patients' clinicopathological characteristics and therapeutic effects were also analyzed. \u0000 \u0000 \u0000Results \u0000There were 43 cases of increased NLR and 43 cases of increased PLR after treatment. NLR and PLR changes before and after neoadjuvant therapy in patients with rectal cancer were not associated with age, gender, TNM stage, lymph node metastasis, number of cancer nodules, and tumor diameter (all P > 0.05). The increasing proportion of NLR and PLR after treatment in patients with the distance from the tumor to anus 0.05). \u0000 \u0000 \u0000Conclusion \u0000NLR changes are associated with therapeutic efficacy before and after neoadjuvant therapy for patients with rectal cancer. \u0000 \u0000 \u0000Key words: \u0000Rectal neoplasms; Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; Neoadjuvant therapy","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":"32 1","pages":"145-148"},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44260820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}